Bls 1 frá 122 niðurstöður
TECHNICAL FIELD OF THE INVENTION
The present invention is directed to novel inhibitors of CD73, processes for their preparation, pharmaceutical compositions containing these inhibitors, and their use in the treatment of cancer and other diseases mediated by CD73.
BACKGROUND OF THE INVENTION
CD73 or
FIELD OF THE INVENTION
The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleotide analogs. More specifically, the invention describes 6-substituted-2-amino purine nucleoside monophosphate and monophosphonate prodrugs and
FIELD OF THE INVENTION
The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleotide analogs. More specifically, the invention describes 6-substituted-2-amino purine nucleoside monophosphate and monophosphonate prodrugs and
The present invention relates to the antitumour and immunomodulatory activities of certain arabinofuranosyl purine derivatives.
It has been reported (Blood, 61, (1983), 660; J. Clin. Invest., 74, (1984), 951 and Cancer Research, 45, (1985), 1008) that arabinofuranosyl guanine (ara G) selectively
FIELD OF THE DISCLOSURE
The present disclosure relates to novel compounds, pharmaceutical compositions containing same and methods for the treatment of cancer using same.
BACKGROUND OF THE DISCLOSURE
A broad group of diseases involving unregulated cell growth is known as cancer or as malignant
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a US National Stage under 35 U.S.C. .sctn.371 of International Application No. PCT/GB2008/050321 (filed May 2, 2008) which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application No. 60/916,270 (filed on May 4,
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
N/A
FIELD OF THE INVENTION
The invention relates to novel compounds and their use to treat diseases.
BACKGROUND OF THE INVENTION
Cancer is prevalent: In the United States, the probability of developing invasive cancer is 38% for females
The invention relates to 2-amino-6-anilino-purine derivatives and to processes and novel intermediates for their preparation, pharmaceutical formulations which comprise such derivatives, and the use of these derivatives as medicaments.
The invention relates to 2-amino-6-anilino-purine derivatives of
BACKGROUND OF THE INVENTION
The Cu-catalyzed version of the classic Huisgen azide-alkyne cycloaddition is a highly atom-economical reaction, often requiring mild conditions. Both factors render Cu-catalyzed azide-alkyne cycloaddition (CuAAC) highly attractive for the modification of complex and
BACKGROUND OF THE INVENTION
This invention relates to purine derivatives, to processes for their preparation, to compositions containing them and to their use.
More particularly, the present invention relates to the use of purine derivatives in the treatment of a variety of viral infections and
FIELD
The present invention relates to purine compounds that may be useful as kinase inhibitors. More particularly, the present invention relates to 2-(morpholin-4-yl), 6-(pyrimidin-5-yl) substituted purine derivatives, methods for their preparation, pharmaceutical compositions containing these
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Phase filing under 35 U.S.C. .sctn.371 of PCT/SG2008/000379 filed Oct. 3, 2008, which claims priority to Provisional Patent Application No. 60/977,720, filed in the United States on Oct. 5, 2007, and Provisional Patent
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to mutant purine nucleoside phosphorylase enzymes having different activity than the non-mutant purine nucleoside phosphorylase enzyme, and to nucleoside substrates for these mutant enzymes. In particular the invention
FIELD OF THE INVENTION
The present invention relates generally to ganciclovir cyclopropanecarboxylate ester derivatives and intermediates, preparation and the use thereof.
BACKGROUND OF THE INVENTION
U.S. Pat. No. 4,162,328 discloses cyclopropane carboxylic acid esters for use as pesticides. U.S.
BACKGROUND OF THE INVENTION
Disease-associated chromatin-modifying enzymes (e.g., DOT1L) play a role in diseases and disorders such as proliferative disorders, metabolic disorders and blood disorders. Thus, there is a need for the development of small molecules that are capable of modulating the